Merriman Curhan Ford maintains a 'Buy' on Depomed (Nasdaq: DEPO), lowers price target range to $7-$8 down from $10-$13.

Merriman ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE